Welcome to our dedicated page for Apyx Medical Corporation SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apyx Medical Corporation (APYX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Apyx Medical’s financial condition, governance, capital markets activity, and material events related to its surgical aesthetics and advanced energy technology business.
Investors can review current reports on Form 8-K, where Apyx Medical discloses items such as quarterly earnings press releases, underwriting agreements for public offerings of common stock, amendments to its Certificate of Incorporation, and voting results from its annual meeting of stockholders. For example, 8-K filings describe the November 2025 underwriting agreement with Lucid Capital Markets, LLC and the December 2025 filing of a Certificate of Amendment removing Article EIGHTH from the company’s Certificate of Incorporation.
The filings page also links to proxy materials like the definitive proxy statement on Schedule 14A, which outlines proposals submitted to stockholders, including director elections, auditor ratification, advisory votes on executive compensation, and charter amendments. These documents provide context on Apyx Medical’s governance structure and stockholder decision-making.
In addition, users can access registration statements referenced in the filings, such as the Form S-3 shelf registration statement used for the company’s public offering, as well as exhibits like underwriting agreements and legal opinions. Stock Titan enhances this information with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand what each document means for Apyx Medical’s operations, financing, and corporate structure.
For those monitoring insider and equity-related activity, the SEC filings set includes disclosures about inducement stock option grants made under Nasdaq Listing Rule 5635(c)(4), as reported in company press releases and incorporated into 8-Ks. Together, these materials form a regulatory record of Apyx Medical’s business and corporate actions.
Apyx Medical Corp Senior Vice President Moshe Citronowicz exercised a stock option to acquire 37,000 shares of common stock at $1.80 per share under the company’s 2015 Share Incentive Plan. Following the transaction, he directly owns 493,504 shares of Apyx Medical common stock, indicating a routine compensation-related increase in his equity stake.
Apyx Medical Corporation reports its annual results highlighting ongoing operating losses alongside new product launches and financing actions. For the year ended December 31, 2025, it recorded a loss from operations of $6.4 million and used $8.0 million of cash in operations, while holding $31.7 million in cash and cash equivalents.
The company advanced its surgical aesthetics portfolio, receiving 510(k) clearance for its AYON body contouring system and beginning a commercial launch in September 2025, and it launched Renuvion in China after local clearance. It also completed a $7.0 million registered direct offering in 2024, a follow-on equity offering in 2025 with net proceeds of about $9.1 million, and put in place a shelf registration for up to $100 million of securities.
Apyx cut costs via a 2024 restructuring that reduced its U.S. workforce by nearly 25%, helping bring 2025 operating expenses below $40.0 million versus $48.2 million in 2024. As of December 31, 2025, it remained in compliance with covenants under its Perceptive Credit Agreement, which includes minimum revenue and maximum operating expense targets and a required $3.0 million cash balance.
Apyx Medical Corporation reported stronger results for the fourth quarter and full year 2025, helped by the U.S. launch of its AYON Body Contouring System. Fourth quarter revenue rose to $19.2 million from $14.2 million, with Surgical Aesthetics sales up 38.1% to about $16.7 million.
Net loss for the quarter narrowed to $1.3 million, or $0.03 per share, compared with $4.6 million, or $0.12 per share, and Adjusted EBITDA improved to a positive $0.7 million from a loss of $2.2 million. For 2025 overall, revenue increased 9.9% to $52.8 million, while net loss attributable to stockholders improved to $11.2 million from $23.5 million.
The company ended 2025 with $31.7 million in cash and cash equivalents and believes its cash can last through 2027. For 2026, it expects total revenue of $57.5 million to $58.5 million, driven by Surgical Aesthetics growth and partially offset by lower OEM revenue, as it continues scaling AYON in the U.S.
APYX Medical Corporation received an updated ownership disclosure from Nantahala Capital Management and its principals. As of December 31, 2025, the reporting group may be deemed to beneficially own 4,112,705 shares of APYX common stock, representing 9.99% of the outstanding shares.
This stake includes 138,614 shares that could be acquired within sixty days through warrant exercises. The shares are held in funds and separately managed accounts controlled by Nantahala, with voting and dispositive power shared among Nantahala, Wilmot B. Harkey, and Daniel Mack. The securities are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of APYX.
Apyx Medical Corp Chief Operating Officer Shawn David Roman reported an option exercise. On January 27, 2026, he exercised a stock option to purchase 12,000 shares of Apyx common stock at $1.80 per share under the company’s 2015 Share Incentive Plan.
The 12,000 shares acquired are held indirectly through The Roman Family Revocable Trust, where he serves as both trustee and beneficiary. Following the transaction, the reported stock option position was reduced to 0 derivative securities, with 12,000 common shares beneficially owned through the trust.
Royce & Associates LP has filed an amended Schedule 13G reporting beneficial ownership of Apyx Medical Corporation common stock. The firm reports beneficial ownership of 2,443,035 shares, representing 5.95% of the outstanding common stock, as of the event date of 12/31/2025. Royce & Associates has sole power to vote and dispose of all of these shares and no shared voting or dispositive power.
The filing explains that the securities are held in one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states that the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Apyx Medical. The firm also disclaims any pecuniary interest and does not consider itself part of a group with Franklin Resources, its affiliates, or their principal shareholders.
Apyx Medical Corporation reported that it has released preliminary revenue results for the fourth quarter and full year ended December 31, 2025. The company disclosed this information through a press release dated January 12, 2026, which is furnished as Exhibit 99.1. The report clarifies that these disclosures are provided under a results of operations and financial condition item and are furnished rather than filed under securities laws, which affects how they are treated for liability purposes.
Apyx Medical Corporation reported that its stockholders approved an amendment to its Certificate of Incorporation at the August 7, 2025 annual meeting to remove Article EIGHTH and replace it with the phrase “intentionally omitted.” On December 8, 2025, the company filed a Certificate of Amendment with the Delaware Secretary of State to put this change into effect, and the full text of the amendment is included as an exhibit.
Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to complete a public offering of its common stock. The Company issued 2,762,431 shares at an offering price of $3.62 per share and granted the underwriter an option to purchase up to an additional 414,365 shares. The offering closed on November 19, 2025, generating approximately $9.4 million in aggregate gross proceeds after a 6.0% underwriting discount and before expenses.
The Company plans to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions of complementary businesses, products or technologies, and repayment of indebtedness it may incur. The transaction was conducted under an existing Form S-3 shelf registration, and customary legal opinions and underwriting documents were filed as exhibits.